Jasper Therapeutics, Inc.
$1.06
▼
-14%
2026-04-21 07:40:01
jaspertx.com
NCM: JSPR
Explore Jasper Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$28.56 M
Current Price
$1.06
52W High / Low
$7.19 / $0.62
Stock P/E
—
Book Value
$0.15
Dividend Yield
—
ROCE
-371.51%
ROE
-2.3%
Face Value
—
EPS
$-3.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
22
Beta
3.2
Debt / Equity
29.75
Current Ratio
2.62
Quick Ratio
2.62
Forward P/E
-0.48
Price / Sales
—
Enterprise Value
$-5 M
EV / EBITDA
0.06
EV / Revenue
—
Rating
Buy
Target Price
$7.7
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AgomAb Therapeutics NV | $10.79 | — | $0.28 M | — | -24.35% | -27.25% | $17.45 / $9 | $-7,123.4 |
| 2. | ImmuCell Corporation | $8.02 | — | $72.74 M | — | 4.28% | -3.81% | $8.23 / $4.52 | $2.99 |
| 3. | Voyager Therapeutics, Inc. | $4.23 | — | $252.11 M | — | -58.41% | -48.29% | $5.55 / $2.65 | $3.32 |
| 4. | Agenus Inc. | $4.42 | 1,529.26 | $175.86 M | — | 21.26% | -0.04% | $7.34 / $1.6 | $-7.68 |
| 5. | Wave Life Sciences Ltd. | $7.58 | — | $1.43 B | — | -39.63% | -54.97% | $21.73 / $5.02 | $2.76 |
| 6. | Ovid Therapeutics Inc. | $2.89 | — | $381.12 M | — | -29.75% | -17.51% | $3.1 / $0.27 | $1 |
| 7. | Dyne Therapeutics, Inc. | $20.02 | — | $3.37 B | — | -41.2% | -55.71% | $25 / $7.38 | $5.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -15.84 M | -19.17 M | -27.08 M | -21.8 M | -25.29 M | — |
| Net Profit | -9.1 M | -18.74 M | -26.72 M | -21.24 M | -24.32 M | — |
| EPS in Rs | -0.33 | -0.67 | -0.95 | -0.76 | -0.87 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -83.88 M | -76.24 M | -68.86 M | -51.2 M |
| Net Profit | -75.8 M | -71.27 M | -64.47 M | -37.69 M |
| EPS in Rs | -2.71 | -2.55 | -2.3 | -1.35 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 35.78 M | 79.9 M | 94.89 M | 48.36 M |
| Total Liabilities | 31.63 M | 18.23 M | 16.45 M | 12.37 M |
| Equity | 4.15 M | 61.67 M | 78.44 M | 35.99 M |
| Current Assets | 34.65 M | 75.81 M | 88.94 M | 41.73 M |
| Current Liabilities | 13.2 M | 15.24 M | 12.37 M | 7.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -77.16 M | -62.6 M | -52.07 M | -45.86 M |
| Investing CF | 0.01 M | -0.53 M | -0.27 M | -0.58 M |
| Financing CF | 34.21 M | 47.88 M | 100.97 M | 0.06 M |
| Free CF | -77.17 M | -63.15 M | -52.33 M | -46.43 M |
| Capex | -0.01 M | -0.55 M | -0.27 M | -0.58 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -10.55% | -71.06% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-01-04 | 1:0.1 |